Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Dose-response Study of Denosumab in Patients with Rheumatoid Arthritis on Methotrexate to Validate Inhibitory Effect on Bone Erosion
jRCT2080221226Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of denosumab in rheumatoid arthritis (RA) (4 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Radiographic change in bone erosion score. Started Sep 2010; status: completed.
02
Drugs
denosumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2080221226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221226.